Trial of potential Ebola treatments begins in DR Congo- WHO

In the Democratic Republic of Congo, a crucial clinical trial has commenced to test two potential treatments for the Bundibugyo species of Ebola. This rare strain has been responsible for the ongoing outbreak in the country's northeastern provinces. The World Health Organization (WHO) announced the trial's launch on Thursday, marking a significant step in combating the virus, for which no approved vaccines or treatments currently exist.

“

Today, the clinical trial of two therapeutics began, with the enrolment of the first patient.

The trial involves the enrollment of the first patient, who will receive comprehensive supportive care alongside close follow-up. The study is evaluating the efficacy and safety of the monoclonal antibody MBP134 and the antiviral drug remdesivir, both individually and in combination. This research is being conducted by the DRC’s National Institute for Biomedical Research, with substantial backing from international partners, including the WHO.

According to WHO figures, the outbreak in the DRC has resulted in 1,406 confirmed cases, with 438 deaths. A total of 208 individuals have recovered from the virus. The WHO chief, Tedros Adhanom Ghebreyesus, expressed optimism about the trial, stating that participants would have access to the drugs should they prove safe and effective. The organization is committed to ensuring these potential therapies become available if the trial yields positive results.

“

Patients who enroll in the trial will receive comprehensive supportive care and close follow-up.

This initiative underscores the global health community's efforts to develop countermeasures against emerging infectious diseases. The trial's success could provide vital tools for managing future outbreaks of this specific Ebola strain, offering hope to affected regions.

“

We are also working to ensure they have access to the two drugs should they prove safe and efficacious in the trial.